Thomas H. Tranah

Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

Vishal Patel, Sunjae Lee, Mark McPhail et al. · Journal of Hepatology · 2021 · 198 citations · Full text

Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis

Thomas H. Tranah, María Pilar Ballester, Juan Antonio Carbonell‐Asins et al. · Journal of Hepatology · 2022 · 113 citations · Full text

Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate

Audrey Dooley, Shiwen Xu, N. Aden et al. · Lara D. Veeken · 2010 · 68 citations · Full text

Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all‐cause admissions in patients on the liver transplant waiting list

Shayon Salehi, Thomas H. Tranah, Samuel Lim et al. · Alimentary Pharmacology & Therapeutics · 2019 · 58 citations · Full text

Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis

María Pilar Ballester, Thomas H. Tranah, Lorenz Balcar et al. · Journal of Hepatology · 2023 · 48 citations · Full text